Feeds:
Posts
Comments

Archive for the ‘Amgen’ Category

*****

Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.

TODAY’S NEWS:

As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just inTasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.

Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injectionmore

Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? – The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predictmore Also – huge sales force push for Prolia.

20% of high school students abuse prescription drugs. Wow – sobering.

RECOMMENDED

Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!

JUST FOR FUN

See-through animals. Ten of them. Amazing.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Advertisements

Read Full Post »

*****

TODAY’S NEWS:

Amgen finally gets approval for Prolia – After months of delay, Amgen finally won FDA approval for Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. The endorsement is a big boost for the biotech, which has been counting on Prolia to reverse a series of setbacks over the past few years, notably a decline in sales of some of its largest-selling products, Aranesp and Enbrelmore

Encouraging early-early-early result? Sure. Overly optimistic headline? Of course. New vaccine “could eliminate breast cancer.” Sally Church gives us some good cautionary words about over-hyping such results.

Biogen sues multiple rivals over MS drug – seeks royalties. I’m sure the lawyers, at least, are happy about this development.

RECOMMENDED

Territory Management Training. We’ve got the vendor/partners you need for this – contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

JOB OPENINGS

Sales and Account Manager, Training Agency serving Life Sciences (Massachusetts), experience required. From the Impactiviti Job Board.

PLUS

Looking Forward to the SPBT Conference – here’s what I’ll be doing, and the workshops that look appealing. Will I see you there? Download my digital business card (see linked post) and let’s get together in Orlando! (SPBT = Society of Pharmaceutical and Biotech Trainers)

JUST FOR FUN

16 Thin Buildings. Actually, I’d prefer to see one thinner consultant, in the mirror. Sigh.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

Abbott making a big India buy – The speculation that has been fuelling the shares of Piramal Healthcare over the past few days has been put to rest after Abbott Laboratories announced Friday that it will buy a unit of the Indian pharmaceutical companymore

Lots of Oncology. Rituxan: cutting lymphoma recurrence – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the diseasemore And, some good news on sarcoma: An experimental drug from Ziopharm Oncology Inc. helped keep fast-growing sarcomas, lethal tumors that can grow to the size of basketballs, in check 77% longer than a standard treatment, a company-sponsored study foundmore Plus, Amgen experimental drugs slow down some tumors.

Some side effects of popular cholesterol-lowering drugs? – Drugs to lower cholesterol and prevent heart disease, taken by millions of people worldwide, increase the risk of cataracts, kidney failure, muscle pain and liver dysfunction, a study of more than 2 million Britons foundmore

RECOMMENDED

Social Media Community/Facebook Moderation and Management. Our social media partners offer a range of services, including community moderation and platform design. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Doctor Won’t See You Now training.

JUST FOR FUN

It’s spring, and the weather’s fine. So, go on one of America’s Scenic Drives.

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Pfizer‘s Chantix (smoke cessation product) under more legal fire for attempted suicides, deaths.

Amgen‘s new drug hopes – Amgen Inc.’s 15-year search for a way to strengthen weak bones led scientists to a medicine that may stop tumors from spreading beyond soft tissue. The discovery may also help revive the company’s fortunes. U.S. regulators are weighing whether to clear the drug, denosumab, to treat the bone-thinning disorder osteoporosis in aging womenmore

Mutant HIV may undo a lot of drug progress. Ugh.

Here’s one person who hates pharma sales reps.

RECOMMENDED

Specialty Sales Training. From full curriculum planning to workshops to targeted courses, we have the providers you need in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

A psychiatrist’s perspective on all of the recent depression discussion.

JUST FOR FUN

Conan O’Brien lists his show for sale on Craig’s List (pretty funny!)

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Takeda buys into Amylin‘s weight-loss drug portfolio – Takeda will pay $75 million upfront for medicines including Amylin’s pramlintide/metreleptin and davalintide, in the second phase of testing needed for U.S. regulatory approval, Osaka- based Takeda and San Diego-based Amylin said in a statementmore Plus, quickie update on three other anti-obesity drugs being developed by various companies.

New lupus treatment (HGS/Glaxo) looking promising on pathway to approval – Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 yearsmore

Vertex HepC drug cures 80%The hepatitis C cure rates of greater than 80% across all four patient groups of the study are also the highest ever recorded in any telaprevir study to date and exceed the cure rates reported in separate studies of boceprevir, a competing hepatitis C drug under development by Schering-Ploughmore

Let’s investigate: Amgen and Shire are the latest.

RECOMMENDED

Meetings. Event planning and execution, logistics, training. We can match you up with the ideal partner(s). Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Not counting on blockbusters – changes, and the future, at Sanofi-Aventis.

JUST FOR FUN

Bayer turns its headquarters into a giant billboard. Pretty eye-catching (watch the video clip).

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

See the newly-re-launched Impactiviti Collection e-newsletter! Here’s a link to the on-line version; you can sign up to receive the Connection (~every two weeks) right here.

TODAY’S NEWS

FDA clears new Novartis combo drug for HBP – The FDA has approved Novartis’ Valturna (aliskiren and valsartan) tablets, a medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS)more

…but says “No” to Sanofi‘s insomnia drug. However, Sanofi did complete the purchase of the Merck half of Merial.

Amgen‘s “mobile rep” strategy for product launch –  Amgen Inc. is hiring flexible, mobile sales representatives as it builds a primary care sales force, a strategy that may allow for a more efficient product launch ahead of the expected regulatory approval of osteoporosis treatment denosumab in mid-October. The launch is likely to be the most important yet for the Thousand Oaks, Calif., biotech, as the drug focuses on primary care physicians in the U.S., a much wider target than its traditional specialty focus. Amgen’s job is made more difficult because the company, unlike traditional pharmaceuticals, is creating the sales force from scratchmore

RECOMMENDED

Virtual Hospital Training. Have to train Hospital sales reps? Maybe an interactive virtual hospital will help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Big picture – what about the future of Big Pharma (I’ve believed for years that a de-verticalization of pharma companies into more compact and focused entities would be very smart). Take a look at this analysis.

JUST FOR FUN

Yummmmmy! And, a Friday bonus: Transparency – not!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Amgen gets approval for one (but not another) indication for their new bone drug – Food and Drug Administration experts unanimously voted that Amgen’s injectable drug denosumab helps prevent bone fractures in women with postmenopausal osteoporosis. But panelists said the drug should only be used by patients who face the greatest risk of fractures. In a separate 12-3 vote, the panel ruled against using the drug as a preventive measure for women with low bone density…more

Schering gets approval for new shizophrenia drug – Schering-Plough Corp. said Friday that the U.S. Food and Drug Administration has approved Saphris tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar disorder in adults. The pharmaceutical company said that Saphris is the first psychotropic drug to receive simultaneous initial approval for both indications…more

King‘s Embeda is approved by FDA: may help counteract pain-pill abuse – The Food and Drug Administration cleared the extended- release morphine product, Embeda, the agency said today in an e- mail. Embeda contains a chemical designed to counteract the morphine if the capsule is crushed, chewed or dissolved in alcohol to get the full dose at once. The company said, and the FDA agreed, the evidence wasn’t conclusive that the chemical truly interfered with the morphine high. More here at the WSJ Health blog.

Allergan‘s Latisse – maybe the new baldness treatment? Stay tuned!

I like to stay on top of early-on encouraging oncology advances. Many don’t pan out, of course. But this sort of result is a nice glimmer!

By the way…are you in need of a vendor/partner to help you develop specialty sales force training? Let me know and I can make a recommendation!

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Twitter: @swoodruff

Read Full Post »

Older Posts »